Beyond improving survival in metastatic disease, clinicians leverage liposomal irinotecan's high tumor shrinkage rate to make borderline resectable or locally advanced pancreatic cancer patients eligible for curative surgery. This strategic use aims to increase the small percentage of patients who can achieve a cure.

Given that standard therapies for metastatic pancreatic cancer are not curative, leading oncologists argue that clinical trials should be the primary consideration for all eligible patients. Standard chemotherapy regimens are viewed as fallback options. This approach frames trials as the best path to advancing care, not an experimental last resort.

For a difficult-to-treat cancer like metastatic pancreatic cancer, improving survival is paramount. Actuate's drug achieved this, but crucially, it did so while adding minimal toxicity to the standard of care. This focus on patient quality of life is a major differentiator and a key factor for treatment adoption.

Oncologists observe that newly diagnosed pancreatic cancer patients now frequently ask about clinical trials. This indicates a significant shift in patient education and empowerment, with individuals actively seeking the most novel treatments available from day one.

Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.

A key future goal in GI oncology is for systemic drugs to become so effective in early disease stages that they diminish or eliminate the need for surgery and radiation. This would spare patients from life-changing procedures like organ removal for gastric, rectal, and pancreatic cancers.

Unlike systemic treatments, which rarely cause pancreatic tumors to shrink on scans, TAMP is demonstrating meaningful radiographic responses. This includes resolving major vessel narrowing, suggesting a more potent local effect and hinting at its potential for converting patients to resectability.

The future of treating advanced pancreatic cancer involves innovative, localized approaches beyond systemic chemotherapy. These include phototherapy to destroy tumor tissue around key blood vessels and transarterial perfusion for direct chemotherapy delivery, aiming to make more patients operable and improve outcomes.

Clinical data revealed a surprising synergy: patients receiving TAMP after chemoradiation had a 60% two-year survival rate. The theory is that radiation remodels the tumor's microvasculature, reducing drug washout and effectively 'priming' the tumor for this regional therapy.